Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 860-873

  MacLaren, Robert ^a   Stringer, Kathleen A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Activated protein C; Acute lung injury; Acute respiratory distress syndrome; ALI; Antithrombin; ARDS; Coagulation; Fibrinolysis; Heparin; Inflammation; Plasminogen activators; t PA; Thrombomodulin; Tissue factor pathway inhibitor; u PA

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; DROTRECOGIN; FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STREPTOKINASE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; ENDOTHELIUM LESION; FIBRINOLYSIS; HOST RESISTANCE; HUMAN; INFLAMMATION; LUNG FUNCTION; MORTALITY; PATHOGENESIS; REVIEW; SEPSIS;

ACUTE DISEASE; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; LUNG DISEASES; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS;

EID: 34249774286     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.860     Document Type: Review

References (105)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319-23.
2. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;61:585-9.
3. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 2006;27:337-49.
4. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury: new therapeutic targets? Keio J Med 2005;54:142-9.
5. Ware LB, Camerer E, Welty-Wolf KE, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291(3):L307-11.
6. Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006;27:365-76.
7. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Crit Care Med 2006;34:871-7.
8. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003;31:S329-36.
9. Sapru A, Wiemels JL, Witte JS, Ware LB, Matthay MA. Acute lung injury and the coagulation pathway: potential role of gene polymorphisms in the protein C and fibrinolytic pathways. Intensive Care Med 2006;32(9):1293-303.
10. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319-27.
11. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
12. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006;21:119-43.
13. MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy 2002;22:1140-56.
14. Frutos-Vivar F, Ferguson ND, Esteban A. Epidemiology of acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006;27:327-36.
15. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93.
16. Mendez JL, Hubmayr RD. New insights into the pathology of acute respiratory failure. Curr Opin Crit Care 2005;11:29-36.
17. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991;261:L240-8.
18. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-62.
19. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J Trauma 1999;47:719-23.
20. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992;3:439-49.
21. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9.
22. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-60.
23. Camerota AJ, Creasey AA, Patla V, Larkin VA, Fink MP. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 1998;177:668-76.
24. Opal SM, Palardy JE, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intraabdominal sepsis. Crit Care Med 2001;29:13-17.
25. Enkhbaatar P, Okajima K, Murakami K, et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000;162:1752-9.
26. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002;26:650-8.
27. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;164:1988-96.
28. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003;167:1200-9.
29. Welty-Wolf KE, Carraway MS, Ortel TL, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006;290:L21-31.
30. Esmon CT. The protein C pathway. Chest 2003;124:26S-32.
31. Redl H, Schlag G, Schiesser A, Davies J. Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J Infect Dis 1995;171:1522-7.
32. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-21.
33. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.
34. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-202.
35. Yamamoto K, Loskutoff DJ. Extrahepatic expression and regulation of protein C in the mouse. Am J Pathol 1998;153:547-55.
36. Taylor FB Jr. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 1994;388:175-94.
37. Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001;163:1660-8.
38. Hasegawa N, Kandra TG, Husari AW, et al. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am J Respir Crit Care Med 1996;153:1831-7.
39. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 1996;271:L470-5.
40. Uchiba M, Okajima K, Murakami K, et al. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation. Am J Physiol 1997;273:L889-94.
41. Gomi K, Zushi M, Honda G, et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990;75:1396-9.
42. Yoshikawa A, Kaido T, Seto S, Katsuura Y, Imamura M. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats. J Hepatol 2000;33:953-60.
43. Maybauer MO, Maybauer DM, Fraser JF, et al. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 2006;34(9):2432-8.
44. Anonymous. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000;342:1301-8.
45. Owings JT, Bagley M, Gosselin R, Romac D, Disbrow E. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma 1996;41:396-405; discussion 405-6.
46. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998;89:233-41.
47. Dschietzig T, Alexiou K, Laule M, et al. Stimulation of pulmonary big endothelin-1 and endothelin-1 by antithrombin III: a rationale for combined application of antithrombin III and endothelin antagonists in sepsis-related acute respiratory distress syndrome? Crit Care Med 2000;28:2445-9.
48. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999;27:597-604.
49. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998;9(suppl 2):S25-37.
50. Salvatierra A, Guerrero R, Rodriguez M, et al. Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog. Circulation 2001;104:2975-80.
51. Harada N, Okajima K, Uchiba M, Kushimoto S, Isobe H. Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb Haemost 2004;92:550-8.
52. Renckens R, Roelofs JJ, Florquin S, et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 2006;177:1189-96.
53. Montes R, Rodriguez-Whilhelmi P, Hurtado V, et al. The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis factor-alpha dependent and can occur in the absence of interleukin-1beta. Thromb Haemost 2002;88:639-43.
54. Saetre T, Lindgaard AK, Lyberg T. Systemic activation of coagulation and fibrinolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul Fibrinolysis 2000;11:433-8.
55. Chapman HA Jr, Stone OL. A fibrinolytic inhibitor of human alveolar macrophages. Induction with endotoxin. Am Rev Respir Dis 1985;132:569-75.
56. Chapman HA, Yang XL, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. J Immunol 1990;145:3398-405.
57. Wygrecka M, Markart P, Ruppert C, et al. Compartment-and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost 2004;92:529-40.
58. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003;31:S213-20.
59. Grau GE, de Moerloose P, Bulla O, et al. Haemostatic properties of human pulmonary and cerebral microvascular endothelial cells. Thromb Haemost 1997;77:585-90.
60. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L20-8.
61. Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T. Fibrinolysis in critically ill patients. Am Rev Respir Dis 1989;140:287-93.
62. Groeneveld AB, Kindt I, Raijmakers PG, Hack CE, Thijs LG. Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome. Thromb Haemost 1997;78:1444-9.
63. Dowdy DW, Eid MP, Dennison CR, et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Med 2006;32:1115-24.
64. Levitt JE, Matthay MA. Treatment of acute lung injury: historical perspective and potential future therapies. Semin Respir Crit Care Med 2006;27:426-37.
65. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173:281-7.
66. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:159-65.
67. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in patients with early acute respiratory distress syndrome (ARDS) significantly improves lung function: results of a randomized controlled trial (RCT) [abstract]. Chest 2005;128(suppl):129S.
68. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-84.
69. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-75.
70. Pontes-Arruda A, Aragao AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006;34:2325-33.
71. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006;34:1033-8.
72. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47.
73. LifeSciencesWorld. Chiron begins phase III trial for tifacogin. May 18, 2004. Available from www.lifesciencesworld.com/rss/tifacogin/news. Accessed October 12, 2006.
74. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915-22.
75. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004;104:3958-64.
76. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-42.
77. Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000;28:2209-16.
78. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
79. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-85.
80. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005;171:1125-8.
81. Manns BJ, Lee H, Doig C, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
82. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.
83. United States National Library of Medicine, National Institutes of Health. Activated protein C to treat acute lung injuries. Updated October 12, 2006. Available from http://www.clinicaltrials.gov/ct/show/NCT00112164?order=1.
84. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-21.
85. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-8.
86. Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42.
87. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
88. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997;8:328-34.
89. Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. J Trauma 1998;45:931-40.
90. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.
91. Malik AB, van der Zee H. Time course of pulmonary vascular response to microembolization. J Appl Physiol 1977;43:51-8.
92. Binder AS, Nakahara K, Ohkuda K, Kageler W, Staub NC. Effect of heparin or fibrinogen depletion on lung fluid balance in sheep after emboli. J Appl Physiol 1979;47:213-19.
93. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br J Haematol 2006;133:62-7.
94. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-8.
95. Cox CS Jr, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993;176:339-49.
96. Abubakar K, Schmidt B, Monkman S, Webber C, deSA D, Roberts R. Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Am J Respir Crit Care Med 1998;158:1620-5.
97. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-30.
98. Stringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997;21:27-34.
99. Abraham E, Gyetko MR, Kuhn K, et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003;170:5644-51.
100. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998;25:184-8.
101. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990;18:1413-18.
102. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001;67:377-82.
103. Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. Adv Ther 1994;11:43-51.
104. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic Biol Med 1997;22:985-8.
105. Dunn JS, Nayar R, Campos J, et al. Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm Res 2005;22:1700-7.